These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 10526669

  • 41. Complex decision-making for BRCA1/2 carriers.
    Matloff ET.
    Cancer J Sci Am; 1999; 5(5):266-8. PubMed ID: 10526666
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.
    Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI.
    J Clin Oncol; 1998 Mar; 16(3):979-85. PubMed ID: 9508180
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Decision-making process of women carrying a BRCA1 or BRCA2 mutation who have chosen prophylactic mastectomy.
    McQuirter M, Castiglia LL, Loiselle CG, Wong N.
    Oncol Nurs Forum; 2010 May; 37(3):313-20. PubMed ID: 20439215
    [Abstract] [Full Text] [Related]

  • 46. Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer.
    Meiser B, Butow P, Barratt A, Friedlander M, Gattas M, Kirk J, Suthers G, Walpole I, Tucker K.
    Gynecol Oncol; 1999 Oct; 75(1):122-9. PubMed ID: 10502438
    [Abstract] [Full Text] [Related]

  • 47. Early cancer detection programmes for women at high risk for breast and ovarian cancer: a proposal of practical guidelines.
    Beckmann MW, Schnürch HG, Bodden-Heidrich R, Mosny DS, Crombach G, Nitz U, Achnoula M, Bender HG.
    Eur J Cancer Prev; 1996 Dec; 5(6):468-75. PubMed ID: 9061278
    [Abstract] [Full Text] [Related]

  • 48. Expanding the criteria for BRCA mutation testing in breast cancer survivors.
    Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B.
    J Clin Oncol; 2010 Sep 20; 28(27):4214-20. PubMed ID: 20733129
    [Abstract] [Full Text] [Related]

  • 49. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
    Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, McTiernan A, Offit K, Perlman J, Petersen G, Thomson E, Varricchio C.
    JAMA; 1997 Mar 26; 277(12):997-1003. PubMed ID: 9091675
    [Abstract] [Full Text] [Related]

  • 50. BRCA genes--bookmaking, fortunetelling, and medical care.
    Healy B.
    N Engl J Med; 1997 May 15; 336(20):1448-9. PubMed ID: 9145684
    [No Abstract] [Full Text] [Related]

  • 51. Prophylactic mastectomy for women with BRCA1 and BRCA2 mutations--facts and controversy.
    Eisen A, Weber BL.
    N Engl J Med; 2001 Jul 19; 345(3):207-8. PubMed ID: 11463017
    [No Abstract] [Full Text] [Related]

  • 52. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.
    Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, Petty PM, Sellers TA, Johnson JL, McDonnell SK, Frost MH, Jenkins RB.
    N Engl J Med; 1999 Jan 14; 340(2):77-84. PubMed ID: 9887158
    [Abstract] [Full Text] [Related]

  • 53. Less correspondence between expectations before and cosmetic results after risk-reducing mastectomy in women who are mutation carriers: a prospective study.
    Brandberg Y, Arver B, Johansson H, Wickman M, Sandelin K, Liljegren A.
    Eur J Surg Oncol; 2012 Jan 14; 38(1):38-43. PubMed ID: 22032910
    [Abstract] [Full Text] [Related]

  • 54. [Clinical counseling and care of women with genetic predisposition to breast and ovarian carcinoma].
    Schmutzler RK, Kempe A, Kiechle M, Beckmann MW.
    Dtsch Med Wochenschr; 1999 May 07; 124(18):563-6. PubMed ID: 10356583
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer.
    Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK.
    J Clin Oncol; 2005 Oct 01; 23(28):6890-8. PubMed ID: 16129845
    [Abstract] [Full Text] [Related]

  • 57. Breast cancer prevention: patient decision making and risk communication in the high risk setting.
    Ozanne EM, Wittenberg E, Garber JE, Weeks JC.
    Breast J; 2010 Oct 01; 16(1):38-47. PubMed ID: 19889168
    [Abstract] [Full Text] [Related]

  • 58. Cost-effectiveness of testing for breast cancer susceptibility genes.
    Holland ML, Huston A, Noyes K.
    Value Health; 2009 Oct 01; 12(2):207-16. PubMed ID: 18647256
    [Abstract] [Full Text] [Related]

  • 59. Prophylactic mastectomy or screening in women suspected to have the BRCA1/2 mutation: a prospective pilot study of women's treatment choices and medical and decision-analytic recommendations.
    Unic I, Verhoef LC, Stalmeier PF, van Daal WA.
    Med Decis Making; 2000 Oct 01; 20(3):251-62. PubMed ID: 10929847
    [Abstract] [Full Text] [Related]

  • 60. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis.
    Grann VR, Jacobson JS, Thomason D, Hershman D, Heitjan DF, Neugut AI.
    J Clin Oncol; 2002 May 15; 20(10):2520-9. PubMed ID: 12011131
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.